This led to experimental support for the incorporation of birinapant, anti-TRAILR antibody, and TRAIL for the treatment of HPV(+) HNSCC cells that were otherwise insensitive to IAP inhibitor birinapant alone. Here, TNFSF10 is linked to head and neck squamous cell carcinoma.